With recently getting the clearance from US FDA for O2VentTM Mono device, Oventus Medical has now successfully registered its listing on the ASX on 19 July 2016 with a fully subscribed IPO. The company’s O2VentTM  range incorporates an airway to bypass nasal, soft palate and tongue obstructions. The company has also registered its next generation O2VentTM T titratable device with the Australian Therapeutic Goods Administration (TGA) and launched the device for consumers through an expanded network of dentists.

Source: http://www.pharmiweb.com/PressReleases/pressrel.asp?ROW_ID=174732#.V5KMl6KRRV0